SCHEMBL17786373

SCHEMBL17786373

Nc1ccc2nc(Cc3ccccc3)[nH]c(=O)c2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.68
▸ MAPT P10636 5/20 0.66
▸ GAA P10253 3/20 0.66
▸ PKM P14618 3/20 0.66
▸ KDM4E B2RXH2 2/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ TUBB4A P04350 1/20 0.54
▸ TUBB P07437 1/20 0.54
▸ TUBA3C P0DPH7 1/20 0.54
▸ TUBA1B P68363 1/20 0.54
▸ TUBA4A P68366 1/20 0.54
▸ TUBB4B P68371 1/20 0.54
▸ TUBB3 Q13509 1/20 0.54
▸ TUBB2A Q13885 1/20 0.54
▸ TUBB8 Q3ZCM7 1/20 0.54
▸ TUBA3E Q6PEY2 1/20 0.54
▸ TUBA1A Q71U36 1/20 0.54
▸ TUBA1C Q9BQE3 1/20 0.54
▸ TUBB6 Q9BUF5 1/20 0.54
▸ TUBB2B Q9BVA1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14282566 0.85 KMT2A (0.72) KMT2AMAPTGAAPKMKDM4E
SCHEMBL7967816 0.84 DHFR (0.49) KMT2AMAPTGAAPKMKDM4E
SCHEMBL27633513 0.83 KMT2A (0.68) KMT2AMAPTGAAPKMKDM4E
SCHEMBL259477 0.83 KMT2A (0.68) KMT2AMAPTGAAPKMKDM4E
SCHEMBL9178009 0.82 KMT2A (1.00) KMT2AMAPTGAAPKMKDM4E
SCHEMBL9131594 0.81 TNKS2 (0.62) KMT2AMAPTGAAPKMKDM4E
SCHEMBL8557293 0.81 MAPT (0.97) KMT2AMAPTGAAPKMKDM4E
SCHEMBL405533 0.81 PDE5A (0.65) KMT2AMAPTGAAPKMKDM4E
SCHEMBL9129643 0.78 KDM4C (0.56) KMT2AMAPTGAAPKMKDM4E
SCHEMBL3762307 0.78 MAPT (0.76) KMT2AMAPTGAAPKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016083490-A1 COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES REMYND NV (BE) 2016-06-02 — — WO disclosed
Send feedback